argenx SE Investor Day Presentation Deck
Forward Looking Statements
Safe Harbor: Certain statements contained in this presentation, other than present and
historical facts and conditions independently verifiable at the date hereof, may constitute
forward-looking statements. Examples of such forward-looking statements include those
regarding the therapeutic and commercial potential of our product candidates; our clinical
development and regulatory plans, including the timing, design and outcome of ongoing and
planned clinical trials and preclinical activities; the timing, progress and benefits of
commercialization activities; our plans to start registrational trials this year; our statements
regarding new assets yearly from IIP; our statements regarding potential and effect of
efgartigimod; our expectation to have IND filing this year; our plan to start Phase 2 trial in
MMN this year; and the expected size of the markets for our product candidates. When used
in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect,"
"intend," "is designed to," "may," "might," "will," "plan," "potential," "predict," "objective,"
"should," or the negative of these and similar expressions identify forward-looking
statements.
Such statements, based as they are on the current analysis and expectations of management,
inherently involve numerous risks and uncertainties, known and unknown, many of which are
beyond the Company's control. Such risks include, but are not limited to: the impact of
COVID-19 pandemic on our business, the impact of general economic conditions, general
conditions in the biopharmaceutical industries, changes in the global and regional regulatory
environments in the jurisdictions in which the Company does or plans to do business, market
volatility, fluctuations in costs and
argenx
changes to the competitive environment. Consequently, actual future results may differ materially
from the anticipated results expressed in the forward-looking statements. In the case of forward-
looking statements regarding investigational product candidates and continuing further
development efforts, specific risks which could cause actual results to differ materially from the
Company's current analysis and expectations include: failure to demonstrate the safety, tolerability
and efficacy of our product candidates; final and quality controlled verification of data and the
related analyses; the expense and uncertainty of obtaining regulatory approval, including from the
U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to
conduct additional clinical trials; our ability to obtain and maintain intellectual property protection
for our product candidates; and our reliance on third parties such as our licensors and
collaboration partners regarding our suite of technologies and product candidates. Further, even if
regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-
going governmental regulation, challenges in gaining market acceptance and competition. These
statements are also subject to a number of material risks and uncertainties that are described in
the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including in
argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings
and reports filed by argenx with the SEC. The reader should not place undue reliance on any
forward-looking statements included in this presentation. These statements speak only as of the
date made and the Company is under no obligation and disavows any obligation to update or
revise such statements as a result of any event, circumstances or otherwise, unless required by
applicable legislation.View entire presentation